Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma.
chemotherapy
distal
neoadjuvant
pancreatic adenocarcinoma
survival
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
revised:
27
07
2024
received:
04
02
2024
accepted:
18
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
Distal pancreatic ductal adenocarcinoma (D-PDAC) often presents at an advanced stage. The efficacy of neoadjuvant therapy (NAT) in improving outcomes for D-PDAC is not well-established. This study evaluates the impact of NAT on the oncological outcomes of patients with D-PDAC. A retrospective cohort study of consecutive patients with resectable and borderline-resectable D-PDAC treated at a single center from 2012 to 2020 was performed. Stratification was based on initial treatment-NAT or surgery first (SF). Survival analysis, following intention-to-treat framework, used Kaplan-Meier and Cox regression to assess NAT's impact on progression-free survival (PFS) and overall survival (OS) of D-PDAC. Among 141 patients (median age 69.8 years, 51.8% females) included in the study, 71 (50.4%) received NAT and 70 (49.6%) were planned for SF. Patients receiving NAT were younger (65.9 vs. 72.6 years) and had higher incidence of borderline-resectable disease (31% vs. 4.3%) (both p < 0.05) than those undergoing SF. Thirteen patients (18.3%) undergoing NAT and five (7.1%) in SF group, failed to undergo resection. Univariate comparison showed no difference in the PFS (SF:13.97 vs. NAT:17.00 months, p = 0.6), and OS (SF:23.73 vs. NAT:32.53 months, p = 0.35). Multivariate Cox regression analysis noted significantly improved PFS (HR = 0.64, 95%CI = 0.42-0.96, p = 0.031) and OS (HR = 0.60, 95%CI = 0.39-0.93, p = 0.021) with NAT. NAT is associated with improved PFS and OS in patients with -D-PDAC. Further randomized controlled trials are warranted to confirm these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Distal pancreatic ductal adenocarcinoma (D-PDAC) often presents at an advanced stage. The efficacy of neoadjuvant therapy (NAT) in improving outcomes for D-PDAC is not well-established. This study evaluates the impact of NAT on the oncological outcomes of patients with D-PDAC.
METHODS
METHODS
A retrospective cohort study of consecutive patients with resectable and borderline-resectable D-PDAC treated at a single center from 2012 to 2020 was performed. Stratification was based on initial treatment-NAT or surgery first (SF). Survival analysis, following intention-to-treat framework, used Kaplan-Meier and Cox regression to assess NAT's impact on progression-free survival (PFS) and overall survival (OS) of D-PDAC.
RESULTS
RESULTS
Among 141 patients (median age 69.8 years, 51.8% females) included in the study, 71 (50.4%) received NAT and 70 (49.6%) were planned for SF. Patients receiving NAT were younger (65.9 vs. 72.6 years) and had higher incidence of borderline-resectable disease (31% vs. 4.3%) (both p < 0.05) than those undergoing SF. Thirteen patients (18.3%) undergoing NAT and five (7.1%) in SF group, failed to undergo resection. Univariate comparison showed no difference in the PFS (SF:13.97 vs. NAT:17.00 months, p = 0.6), and OS (SF:23.73 vs. NAT:32.53 months, p = 0.35). Multivariate Cox regression analysis noted significantly improved PFS (HR = 0.64, 95%CI = 0.42-0.96, p = 0.031) and OS (HR = 0.60, 95%CI = 0.39-0.93, p = 0.021) with NAT.
CONCLUSION
CONCLUSIONS
NAT is associated with improved PFS and OS in patients with -D-PDAC. Further randomized controlled trials are warranted to confirm these findings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The authors received no specific funding for this work.
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Surveillance Research Program, National Cancer Institute, 2023, https://seer.cancer.gov/statistics-network/explorer/.
F. N. van Erning, T. M. Mackay, L. G. M. van der Geest, et al., “Association of the Location of Pancreatic Ductal Adenocarcinoma (Head, Body, Tail) With Tumor Stage, Treatment, and Survival: A Population‐Based Analysis,” Acta Oncologica 57, no. 12 (December 2018): 1655–1662, https://doi.org/10.1080/0284186X.2018.1518593.
L. K. Winer, V. K. Dhar, K. Wima, et al., “The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma,” Journal of Surgical Research 239 (July 2019): 60–66, https://doi.org/10.1016/j.jss.2019.01.061.
L. M. Youngwirth, D. P. Nussbaum, S. Thomas, et al., “Nationwide Trends and Outcomes Associated With Neoadjuvant Therapy in Pancreatic Cancer: An Analysis of 18243 Patients,” Journal of Surgical Oncology 116, no. 2 (August 2017): 127–132, https://doi.org/10.1002/jso.24630.
Y. Nagakawa, Y. Sahara, Y. Hosokawa, et al., “Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery,” Annals of Surgical Oncology 26, no. 6 (June 2019): 1629–1636, https://doi.org/10.1245/s10434-018-07131-8.
H. X. Zhan, J. W. Xu, D. Wu, et al., “Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta‐Analysis of Prospective Studies,” Cancer Medicine 6, no. 6 (June 2017): 1201–1219, https://doi.org/10.1002/cam4.1071.
E. Versteijne, M. Suker, K. Groothuis, et al., “Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial,” Journal of Clinical Oncology 38, no. 16 (2020): 1763–1773, https://doi.org/10.1200/JCO.19.02274.
J. E. Murphy, J. Y. Wo, D. P. Ryan, et al., “Total Neoadjuvant Therapy with Folfirinox Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial,” JAMA Oncology 4, no. 7 (July 2018): 963–969, https://doi.org/10.1001/jamaoncol.2018.0329.
J. M. Cloyd, V. Heh, T. M. Pawlik, et al., “Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta‐Analysis of Randomized Controlled Trials,” Journal of Clinical Medicine 9, no. 4 (April 2020): 1129, https://doi.org/10.3390/jcm9041129.
F. I. Macedo, E. Ryon, S. K. Maithel, et al., “Survival Outcomes Associated with Clinical and Pathological Response Following Neoadjuvant Folfirinox or Gemcitabine/Nab‐Paclitaxel Chemotherapy in Resected Pancreatic Cancer,” Annals of Surgery 270, no. 3 (September 2019): 400–413, https://doi.org/10.1097/SLA.0000000000003468.
V. Bernard, D. U. Kim, F. A. San Lucas, et al., “Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer,” Gastroenterology 156, no. 1 (January 2019): 108–118.e4, https://doi.org/10.1053/j.gastro.2018.09.022.
A. I. Al Abbas, M. Zenati, C. J. Reiser, et al., “Serum CA19‐9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma,” Ann Surg Oncol 27, no. 6 (2020): 2007–2014, https://doi.org/10.1245/s10434-019-08156-3.
S. Lof, M. Korrel, J. van Hilst, et al., “Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity‐Score Matched Multicenter Study,” Annals of Surgical Oncology 27, no. 6 (June 2020): 1986–1996, https://doi.org/10.1245/s10434-019-08137-6.
I. Nassour, M. A. Adam, S. Kowalsky, et al., “Neoadjuvant Therapy Versus Upfront Surgery for Early‐Stage Left‐Sided Pancreatic Adenocarcinoma: A Propensity‐Matched Analysis From a National Cohort of Distal Pancreatectomies,” Journal of Surgical Oncology 123, no. 1 (2021): 245–251, https://doi.org/10.1002/jso.26267.
L. M. Ocuin, J. M. Hardacre, J. B. Ammori, et al., “Neoadjuvant Chemotherapy Is Associated With Improved Survival in Patients with Left‐Sided Pancreatic Adenocarcinoma,” Journal of Surgical Oncology 122, no. 8 (2020): 1595–1603, https://doi.org/10.1002/jso.26196.
National Comprehensive Cancer Network, Pancreatic cancer (Version 1.2020), 2020, https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
M. Charlson, T. P. Szatrowski, J. Peterson, and J. Gold, “Validation of a Combined Comorbidity Index,” Journal of Clinical Epidemiology 47 (1994): 1245–1251.
A. J. Mangram, T. C. Horan, M. L. Pearson, L. C. Silver, and W. R. Jarvis, “Guideline for Prevention of Surgical Site Infection, 1999,” Infection Control & Hospital Epidemiology 20, no. 4 (1999): 247–280.
C. Bassi, G. Marchegiani, C. Dervenis, et al., “The 2016 Update of the International Study Group (ISGPS) Definition and Grading of Postoperative Pancreatic Fistula: 11 Years After,” Surgery 161, no. 3 (March 2017): 584–591, https://doi.org/10.1016/j.surg.2016.11.014.
D. Dindo, N. Demartines, and P. A. Clavien, “Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey,” Annals of Surgery 240, no. 2 (2004): 205–213.
Y. S. Chun, T. M. Pawlik, and J. N. Vauthey, “8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers,” Annals of Surgical Oncology 25, no. 4 (April 2018): 845–847.
J. Neoptolemos, J. Dunn, D. Stocken, et al., “Adjuvant Chemoradiotherapy and Chemotherapy in Resectable Pancreatic Cancer: A Randomised Controlled Trial,” Lancet 358, no. 9293 (November 2001): 1576–1585.
J. P. Neoptolemos, D. D. Stocken, H. Friess, et al., “A Randomized Trial of Chemoradiotherapy and Chemotherapy After Resection of Pancreatic Cancer,” New England Journal of Medicine 350, no. 12 (March 2004): 1200–1210.
R. H. Nanda, B. El‐Rayes, S. K. Maithel, and J. Landry, “Neoadjuvant Modified Folfirinox and Chemoradiation Therapy for Locally Advanced Pancreatic Cancer Improves Resectability,” Journal of Surgical Oncology 111, no. 8 (June 2015): 1028–1034, https://doi.org/10.1002/jso.23921.
J. Wong, “Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma,” World Journal of Clinical Oncology 7, no. 1 (February 2016): 1–8, https://doi.org/10.5306/wjco.v7.i1.1.
A. Artinyan, P. A. Soriano, C. Prendergast, T. Low, J. D. I. Ellenhorn, and J. Kim, “The Anatomic Location of Pancreatic Cancer Is a Prognostic Factor for Survival,” HPB 10, no. 5 (2008): 371–376, https://doi.org/10.1080/13651820802291233.
G. Tomasello, M. Ghidini, A. Costanzo, et al., “Outcome of Head Compared to Body and Tail Pancreatic Cancer: A Systematic Review and Meta‐Analysis of 93 Studies,” Journal of Gastrointestinal Oncology 10, no. 2 (April 2019): 259–269, https://doi.org/10.21037/jgo.2018.12.08.
I. Nassour, S. B. Winters, R. Hoehn, et al., “Long‐Term Oncologic Outcomes of Robotic and Open Pancreatectomy in a National Cohort of Pancreatic Adenocarcinoma,” J Surg Oncol 122, no. 2 (2020): 234–242, https://doi.org/10.1002/jso.25958.
G. Quero, N. Pecorelli, S. Paiella, et al., “Pancreaticoduodenectomy in Octogenarians: The Importance of “Biological Age” on Clinical Outcomes,” Surgical Oncology 40 (2022): 101688, https://doi.org/10.1016/j.suronc.2021.101688.
A. B. Blair, R. Sorber, N. S. Rozich, and R. A. Burkhart, “A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma,” Pancreas 48, no. 8 (September 2019): 973–984, https://doi.org/10.1097/MPA.0000000000001376.
A. Irfan, J. B. Rose, T. N. Wang, et al., “The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy,” Pancreas 51, no. 1 (January 2022): 100–105, https://doi.org/10.1097/MPA.0000000000001972.
S. A. Ahmad, M. Duong, D. P. S. Sohal, et al., “Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab‐Paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma,” Annals of Surgery 272, no. 3 (September 2020): 481–486, https://doi.org/10.1097/SLA.0000000000004155.
J. L. van Dam, Q. P. Janssen, M. G. Besselink, et al., “Neoadjuvant Therapy or Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Meta‐Analysis of Randomised Controlled Trials,” European Journal of Cancer 160 (2022): 140–149, https://doi.org/10.1016/j.ejca.2021.10.023.
B. A. Boone, J. Steve, M. S. Zenati, et al., “Serum CA 19‐9 Response to Neoadjuvant Therapy Is Associated With Outcome in Pancreatic Adenocarcinoma,” Annals of Surgical Oncology 21, no. 13 (December 2014): 4351–4358, https://doi.org/10.1245/s10434-014-3842-z.
E. A. Mellon, W. H. Jin, J. M. Frakes, et al., “Predictors and Survival for Pathologic Tumor Response Grade in Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Induction Chemotherapy and Neoadjuvant Stereotactic Body Radiotherapy,” Acta Oncologica 56, no. 3 (March 2017): 391–397, https://doi.org/10.1080/0284186X.2016.1256497.
D. Chatterjee, M. H. Katz, W. C. Foo, et al., “Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy,” American Journal of Surgical Pathology 41, no. 8 (August 2017): 1097–1104, https://doi.org/10.1097/PAS.0000000000000887.
H. Oettle, P. Neuhaus, A. Hochhaus, et al., “Adjuvant Chemotherapy with Gemcitabine and Long‐Term Outcomes Among Patients With Resected Pancreatic Cancer: the CONKO‐001 Randomized Trial,” JAMA 310, no. 14 (2013): 1473–1481, https://doi.org/10.1001/jama.2013.279201.
W. Wu, J. He, J. L. Cameron, et al., “The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma,” Annals of Surgical Oncology 21, no. 9 (September 2014): 2873–2881, https://doi.org/10.1245/s10434-014-3722-6.
M. J. Truty, M. L. Kendrick, D. M. Nagorney, et al., “Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer,” Annals of Surgery 273, no. 2 (2021): 341–349, https://doi.org/10.1097/SLA.0000000000003284.
S. Schorn, I. E. Demir, N. Samm, et al., “Meta‐Analysis of the Impact of Neoadjuvant Therapy on Patterns of Recurrence in Pancreatic Ductal Adenocarcinoma,” BJS Open 2, no. 2 (March 2018): 52–61, https://doi.org/10.1002/bjs5.46.
P. Papavasiliou, J. P. Hoffman, S. J. Cohen, J. E. Meyer, J. C. Watson, and Y. S. Chun, “Impact of Preoperative Therapy on Patterns of Recurrence in Pancreatic Cancer,” HPB: the official journal of the International Hepato Pancreato Biliary Association 16, no. 1 (January 2014): 34–39, https://doi.org/10.1111/hpb.12058.
M. Dhir, M. S. Zenati, A. Hamad, et al., “FOLFIRINOX Versus Gemcitabine/Nab‐Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma,” Annals of Surgical Oncology 25, no. 7 (July 2018): 1896–1903, https://doi.org/10.1245/s10434-018-6512-8.
T. J. Vreeland, F. McAllister, S. Javadi, et al., “Benefit of Gemcitabine/Nab‐Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX,” Pancreas 48, no. 6 (July 2019): 837–843, https://doi.org/10.1097/MPA.0000000000001345.